Detalhe da pesquisa
1.
High-Throughput Antigen Microarray Identifies Longitudinal Prognostic Autoantibody for Chemoimmunotherapy in Advanced Non-Small Cell Lung Cancer.
Mol Cell Proteomics
; 23(5): 100749, 2024 May.
Artigo
Inglês
| MEDLINE | ID: mdl-38513890
2.
Proteomics Identifies Circulating TIMP-1 as a Prognostic Biomarker for Diffuse Large B-Cell Lymphoma.
Mol Cell Proteomics
; 22(9): 100625, 2023 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37500057
3.
Identification of novel prognostic autoantibodies in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone via a high-throughput antigen microarray.
Cancer
; 130(8): 1257-1269, 2024 Apr 15.
Artigo
Inglês
| MEDLINE | ID: mdl-38133926
4.
Longitudinal plasma proteomic analysis identifies biomarkers and combinational targets for anti-PD1-resistant cancer patients.
Cancer Immunol Immunother
; 73(3): 47, 2024 Feb 13.
Artigo
Inglês
| MEDLINE | ID: mdl-38349411
5.
Long-term outcomes with HLX01 (HanliKang®), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study.
BMC Cancer
; 24(1): 124, 2024 Jan 24.
Artigo
Inglês
| MEDLINE | ID: mdl-38267866
6.
Development and validation of a novel risk stratification model and a survival rate calculator for diffuse large B-cell lymphoma in the rituximab era: a multi-institutional cohort study.
Ann Hematol
; 103(1): 211-226, 2024 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-37861735
7.
Identification of an antigen-presenting cells/T/NK cells-related gene signature to predict prognosis and CTSL to predict immunotherapeutic response for lung adenocarcinoma: an integrated analysis of bulk and single-cell RNA sequencing.
Cancer Immunol Immunother
; 72(10): 3259-3277, 2023 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-37458771
8.
Immune checkpoint inhibitors combined with angiogenic inhibitors in the treatment of locally advanced or metastatic lung adenocarcinoma patients.
Cancer Immunol Immunother
; 72(2): 449-459, 2023 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-35934742
9.
Identification of novel serological autoantibodies in Chinese prostate cancer patients using high-throughput protein arrays.
Cancer Immunol Immunother
; 72(1): 235-247, 2023 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-35831618
10.
Integrative analyses of bulk and single-cell RNA-seq identified cancer-associated fibroblasts-related signature as a prognostic factor for immunotherapy in NSCLC.
Cancer Immunol Immunother
; 72(7): 2423-2442, 2023 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-37010552
11.
Efficacy and safety of geptanolimab (GB226) for relapsed/refractory primary mediastinal large B-cell lymphoma: an open-label phase II study (Gxplore-003).
Cancer Immunol Immunother
; 72(9): 2991-3002, 2023 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-37289256
12.
Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study.
BMC Med
; 21(1): 11, 2023 01 08.
Artigo
Inglês
| MEDLINE | ID: mdl-36617560
13.
Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT).
BMC Med
; 21(1): 72, 2023 02 24.
Artigo
Inglês
| MEDLINE | ID: mdl-36829154
14.
Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies.
BMC Med
; 21(1): 164, 2023 04 28.
Artigo
Inglês
| MEDLINE | ID: mdl-37118803
15.
Incidence, survival comparison, and novel prognostic evaluation approaches for stage iii-iv pulmonary large cell neuroendocrine carcinoma and small cell lung cancer.
BMC Cancer
; 23(1): 312, 2023 Apr 05.
Artigo
Inglês
| MEDLINE | ID: mdl-37020179
16.
Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer: a phase Ib study.
BMC Cancer
; 23(1): 331, 2023 Apr 11.
Artigo
Inglês
| MEDLINE | ID: mdl-37041472
17.
Efficacy and safety of PD-1 monoclonal antibody plus rituximab in relapsed/refractory diffuse large B cell lymphoma patients.
Eur J Haematol
; 111(3): 356-364, 2023 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-37294015
18.
High-throughput and multi-phases identification of autoantibodies in diagnosing early-stage breast cancer and subtypes.
Cancer Sci
; 113(2): 770-783, 2022 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-34843149
19.
Brain metastases and immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis.
Cancer Immunol Immunother
; 71(12): 3071-3085, 2022 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-35648238
20.
Anti-PD1/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapy.
Cancer Immunol Immunother
; 71(7): 1681-1691, 2022 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-34817638